Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions

Karen J. Doyle, Christine E. McLaren, Janet E. Shanks, Cheryl M. Galus, Frank L. Meyshens

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: To determine the effects of long-term, lowdose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans. Design: A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp. Setting: Academic tertiary care referral center. Participants: One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz. Interventions: Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m 2 of body surface area for 12 months. Outcome Measures: Pure-tone audiometric thresholds for the frequencies 250,500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement. Results: At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz. Conclusions: Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.

Original languageEnglish (US)
Pages (from-to)553-558
Number of pages6
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume127
Issue number5
StatePublished - May 2001

Fingerprint

Eflornithine
Audiometry
Chemoprevention
Hearing
Placebos
Tertiary Care Centers
Colonic Polyps
Adenomatous Polyps
Withholding Treatment
Body Surface Area
Polyps
Hearing Loss
Volunteers
Outcome Assessment (Health Care)
Clinical Trials

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Doyle, K. J., McLaren, C. E., Shanks, J. E., Galus, C. M., & Meyshens, F. L. (2001). Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. Archives of Otolaryngology - Head and Neck Surgery, 127(5), 553-558.

Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. / Doyle, Karen J.; McLaren, Christine E.; Shanks, Janet E.; Galus, Cheryl M.; Meyshens, Frank L.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 127, No. 5, 05.2001, p. 553-558.

Research output: Contribution to journalArticle

Doyle, KJ, McLaren, CE, Shanks, JE, Galus, CM & Meyshens, FL 2001, 'Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions', Archives of Otolaryngology - Head and Neck Surgery, vol. 127, no. 5, pp. 553-558.
Doyle, Karen J. ; McLaren, Christine E. ; Shanks, Janet E. ; Galus, Cheryl M. ; Meyshens, Frank L. / Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. In: Archives of Otolaryngology - Head and Neck Surgery. 2001 ; Vol. 127, No. 5. pp. 553-558.
@article{d14849d97beb48eba7c60ff638e87b8d,
title = "Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions",
abstract = "Objectives: To determine the effects of long-term, lowdose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans. Design: A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp. Setting: Academic tertiary care referral center. Participants: One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz. Interventions: Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m 2 of body surface area for 12 months. Outcome Measures: Pure-tone audiometric thresholds for the frequencies 250,500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement. Results: At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz. Conclusions: Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.",
author = "Doyle, {Karen J.} and McLaren, {Christine E.} and Shanks, {Janet E.} and Galus, {Cheryl M.} and Meyshens, {Frank L.}",
year = "2001",
month = "5",
language = "English (US)",
volume = "127",
pages = "553--558",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions

AU - Doyle, Karen J.

AU - McLaren, Christine E.

AU - Shanks, Janet E.

AU - Galus, Cheryl M.

AU - Meyshens, Frank L.

PY - 2001/5

Y1 - 2001/5

N2 - Objectives: To determine the effects of long-term, lowdose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans. Design: A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp. Setting: Academic tertiary care referral center. Participants: One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz. Interventions: Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m 2 of body surface area for 12 months. Outcome Measures: Pure-tone audiometric thresholds for the frequencies 250,500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement. Results: At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz. Conclusions: Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.

AB - Objectives: To determine the effects of long-term, lowdose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans. Design: A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp. Setting: Academic tertiary care referral center. Participants: One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz. Interventions: Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m 2 of body surface area for 12 months. Outcome Measures: Pure-tone audiometric thresholds for the frequencies 250,500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement. Results: At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz. Conclusions: Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.

UR - http://www.scopus.com/inward/record.url?scp=0035036630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035036630&partnerID=8YFLogxK

M3 - Article

C2 - 11346432

AN - SCOPUS:0035036630

VL - 127

SP - 553

EP - 558

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 5

ER -